Arctic Bioscience adjusted EBITDA loss narrows to NOK 12.1 million in H1 FY26; revenue rises 35.2% to NOK 23.3 million vs H1 FY25

• Arctic Bioscience posted H1 2026 sales revenue of NOK 23.3 million, up 35.2% year over year, with supplier delays pushing some shipments into July.
• Adjusted EBITDA loss narrowed to NOK 12.1 million in H1, while available liquidity fell to NOK 1.2 million at period end.
• Gross profit rose to NOK 6.9 million, lifting gross margin to 29.8%.
• US sales revenue climbed to NOK 9.7 million, up 87% year over year, representing 41.8% of total sales revenue.
• Management reiterated a positive 2026 sales outlook, citing a robust order pipeline, while advancing Phase III planning for HRO350 and partnership talks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arctic Bioscience AS published the original content used to generate this news brief via Cision (Ref. ID: 20260826:BIT:2706:0) on August 27, 2026, and is solely responsible for the information contained therein.